Le Chevalier T, Arriagada R, Baldeyrou P, de Cremoux H, Ruffié P, Martin M, Cerrina M L, de Thé G, Sancho-Garnier H, Hayat M
Institut Gustave-Roussy, Villejuif, France.
Bull Cancer. 1987;74(5):559-64.
One hundred and nine patients with limited small cell lung carcinoma were entered in a phase II study alternating six cycles of combination chemotherapy and three courses of mediastinal radiotherapy. Chemotherapy consisted of doxorubicin 40 mg/m2 day 1, etoposide 75 mg/m2 days 1, 2, 3, cyclophosphamide 300 mg/m2 days 3, 4, 5, 6, and methotrexate 400 mg/m2 day 2 (+folinic acid rescue) or cisplatin 100 mg/m2 day 2. The total mediastinal radiation dose was 45 or 55 Gy. A 6 to 8 cycle maintenance chemotherapy followed this induction protocol. The complete remission rate at the end of the induction therapy was 79%. The local recurrence rate was 25% and the distant metastases rate was 52%. Median survival is 17.2 +/- 1.2 months and survival rate at 3 years is 26%. Lethal toxicity occurred in 3% of patients during induction therapy, and long term survivors are being evaluated. Our results justify further investigations with this alternating schedule.
109例局限期小细胞肺癌患者进入一项II期研究，接受6个周期联合化疗与3个疗程纵隔放疗交替进行的治疗。化疗方案为：阿霉素40mg/m²，第1天；依托泊苷75mg/m²，第1、2、3天；环磷酰胺300mg/m²，第3、4、5、6天；甲氨蝶呤400mg/m²，第2天（+亚叶酸钙解救）或顺铂100mg/m²，第2天。纵隔总放疗剂量为45或55Gy。诱导治疗后进行6至8个周期的维持化疗。诱导治疗结束时的完全缓解率为79%。局部复发率为25%，远处转移率为52%。中位生存期为17.2±1.2个月，3年生存率为26%。诱导治疗期间3%的患者发生致命毒性，目前正在对长期存活者进行评估。我们的结果证明进一步研究这种交替方案是合理的。
